Urine Drug Testing Frequency: When the Calendar Becomes the Order

Urine drug testing frequency under Medicare depends on the patient’s clinical need and the coverage policy governing the claim. There is no single national testing schedule for every patient. The problem begins when a practice or laboratory lets the calendar make the decision: the same tests, at every visit, for everyone. If you work with requisitions, laboratory results or billing, that is the question we answer with you: who decided this patient needed this test again.

Preferred Pain Management & Spine Care shows how that question becomes a case. In its April 2021 settlement announcement, the Justice Department alleged that the practice automatically ordered both presumptive and definitive urine drug tests for all patients at their monthly visits. The government said the practice skipped individualized assessments of need or risk. A recurring appointment had become a recurring pair of tests.

How Often Does Medicare Cover Urine Drug Testing?

Medicare coverage for urine drug testing depends on why testing is needed, which method is ordered and the applicable local coverage determination. Pain management and substance-use treatment have different clinical purposes and different frequency provisions. The patient’s history, medications, treatment stage and risk assessment give the testing interval its meaning. When a blanket order replaces that judgment, taxpayers pay for the routine.

Wisconsin Physicians Service’s urine drug testing policy, L34645, has a revision effective August 28, 2025. CGS Administrators’ policy, L36029, covering Kentucky and Ohio, has a revision effective March 5, 2026. CMS identifies both versions as currently in effect. These are local contractor policies, and their limits belong with the jurisdiction and service date of the claim being examined.

A historical claim needs the policy version that governed its service date. CGS says its March 2026 annual review made no changes.

Chronic Opioid Therapy Depends on Documented Risk

The WPS and CGS monitoring provisions set these frequencies for patients receiving chronic opioid therapy:

• Low risk: up to two presumptive and two definitive tests in a rolling 365 days.
• Moderate risk: up to two presumptive and two definitive tests in a rolling 180 days.
• High risk: up to three presumptive and three definitive tests in a rolling 90 days.

Each category still requires documented medical necessity and clinician review. The policies also describe clinical reasons for additional definitive testing, including a change in medication response or side effects, possible drug interactions, or a change in the patient’s condition. The risk category explains the starting frequency. The medical record explains the additional test.

Substance-Use Treatment Depends on the Stage of Recovery

For substance-use treatment, both versions organize frequency by consecutive days of abstinence:

• Zero through 30 days: up to three presumptive tests and one definitive test in a rolling seven days.
• 31 through 90 days: up to three presumptive tests in a rolling seven days and three definitive tests in a rolling 30 days.
• More than 90 days: up to three presumptive tests in a rolling 30 days and three definitive tests in a rolling 90 days.

The clinician must document the rationale for the drugs or drug classes selected and use the results to direct care. A facility’s weekly collection schedule supplies neither of those things.

Presumptive and Definitive Testing Answer Different Questions

Presumptive testing screens for drugs or drug classes. Definitive testing identifies specific drugs and metabolites, commonly through GC-MS or LC-MS/MS. Frequency counts testing encounters over time. The method and the number of drug classes describe what happened within an encounter.

An immunoassay can miss a drug it detects poorly, or react to another substance. A negative screen can therefore leave a clinical question unanswered. Both policies allow direct definitive testing when individualized medical documentation supports it. The sequence depends on the patient and the clinical question.

After a point-of-care screen, these policies require the clinician to decide whether further definitive testing is needed and order the specific tests.

Clinical interpretation matters to frequency as well. The 2014 Pain Physician paper Ethical Perspectives on Urine Drug Screening for Pain Physicians explains that detection windows vary and that results need clinical context. The result, the medication history and the reason for repeating the test belong together.

When Are Toxicology Tests Unnecessary?

Toxicology tests are unnecessary when the ordered testing lacks a patient-specific clinical purpose, including blanket testing that substitutes a practice-wide routine for an individual decision. The WPS and CGS policies distinguish a standing order for a particular patient over a limited series of visits from an identical order applied to everyone. The clinician can alter the individual standing order as the patient’s circumstances change.

The Journal of Family Practice’s 2021 review, Urine Drug Screening: A Guide to Monitoring Tx With Controlled Substances, describes an approach that separates collecting a sample from testing it:

The review describes frequency changing with ongoing assessment, including results and behavior. It notes that routine testing at every visit is often unnecessary for stable patients. The Medicare policies also recommend random intervals and say testing need not coincide with an office visit. The appointment book is a poor substitute for that clinical judgment.

A Definitive Urine Panel Ordered Regardless of Prescribed Medication

A definitive urine panel ordered regardless of prescribed medication raises a question about who selected the drugs and why. These policies require the clinician to select tests based on the individual patient’s clinical history and risk and document that decision in the medical record.

Genotox Laboratories admitted in its 2023 civil settlement that it offered forms allowing providers to preselect tests for all or nearly all their patients, generally in the highest reimbursement categories, including definitive testing for 22 or more drug classes, the tier billed under G0483. A provider’s selection became a repeated laboratory instruction.

The whistleblower’s complaint alleged that even the terminology changed:

Calling the profile custom says little about whose needs it reflects. The order form, the drugs actually tested and the patient’s record show whether anyone made an individual choice. This is where a laboratory employee who knows how profiles are created can see something the claim itself conceals.

A Monthly Definitive UDT Panel With No Documented Clinical Change

A monthly definitive UDT panel with no documented clinical change needs a patient-specific explanation for the recurring testing. For additional definitive tests beyond the chronic-opioid monitoring recommendations, the policies call for the clinician’s justification and identify circumstances such as changed medication response or possible interactions.

Preferred Pain agreed to pay $789,293 to resolve allegations of medically unnecessary testing billed to Medicare, Medicaid and other federal health care programs. The alleged conduct ran from June 2014 through May 2017.

For someone inside a practice, the recurring order and the result review are separate parts of that story. The order shows what would happen at the next visit. The clinical notes show what the practitioner learned from the last test and why another was needed. When the same panel keeps running, we examine the instructions that keep it running alongside the medical rationale.

The WPS and CGS policies require results to inform care. A laboratory can produce an accurate result while the reason for ordering that result remains missing from the patient’s record. That gap is where the frequency inquiry becomes more useful than simply counting visits.

Are Three Weekly Drug Tests in a Residential Program Medically Necessary?

Three weekly drug tests in a residential program require a patient-specific medical necessity assessment under the applicable coverage policy. The type of test, treatment stage, clinician’s order and use of the result all matter. A sober home’s requirement that residents provide samples describes the program’s monitoring routine. The clinical record must explain the medical service billed.

GENCO Lab agreed to pay $1,255,825 in August 2025 to settle allegations involving testing from September 2021 through December 2023. The government alleged that the laboratory billed Medicare and Medicaid for tests performed solely for residential monitoring of sober-home residents, a prohibited purpose.

The same announcement described a separate duplication problem. GENCO allegedly routinely performed presumptive and definitive testing at the same time on the same day. No practitioner first reviewed the screening result to decide whether the more expensive definitive test was needed. Government programs received bills for both types each time.

Those allegations identify what a resident-testing calendar can hide: the reason for the collection, the reason for each method and the decision connecting the result to care. The treatment purpose has to survive the trip from the sober home to the laboratory claim.

Can Specimen Validity Testing Be Billed Separately?

Under these Medicare policies, testing performed to check the urine specimen’s validity is quality assurance and is not separately payable. Checks can include creatinine, pH, specific gravity and oxidants. Their purpose is to assess whether the sample is consistent with human urine and has been adulterated or substituted.

The Preferred Pain allegations included separately billed specimen-validity testing during 2014 and 2015, despite Medicare guidance against that billing. Repeating a quality-control charge with every visit can add another claim to the recurring testing pattern.

The WPS and CGS versions also address repeat presumptive testing across providers. They limit payment to one presumptive result per patient per service date when both an office and a reference laboratory perform that testing. The second location can be as important as the next appointment. These policies also exclude testing urine and another specimen type from the same patient on the same day for the same drugs or metabolites.

The Billing Pattern Behind the Calendar

A frequency review follows the patient, order, performed tests, results and clinical response into the claim. Presumptive codes 80305 through 80307 and definitive codes G0480 through G0483 distinguish the method and drug-class tier. A broad definitive panel and frequent testing expand different parts of the bill.

The industry’s documentation split makes this work harder. The ordering practitioner maintains the medical justification in the patient’s record. The laboratory maintains what it received and the information it submitted with the claim. We use your knowledge of the order forms and billing instructions to establish who directed the repeated claims and what the patient records support. A billing history shows the repetition. The clinical record and order instructions explain how it arose.

Referral arrangements can explain another part of the pattern. Cordant Health Solutions’ 2020 settlement addressed allegations of payments for urine-testing referrals. The relationship bringing specimens to the laboratory deserves attention alongside the schedule generating them.

Pacific Toxicology Laboratories’ 2024 settlement resolved allegations that separately billed testing for opioid treatment program patients caused Medicare to pay twice for services already included in the program payment. That pattern reaches the payment arrangement as well as the testing calendar.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. For a healthcare insider, knowledge of who built the recurring order, chose the panel or instructed the billing connects repeated claims to decisions inside the business.

When You Know Why the Tests Keep Running

If you know how a blanket order becomes months of urine-testing claims, talk with our whistleblower experts about the pattern inside your practice or laboratory. We work with you to build your strongest laboratory fraud whistleblower case around the orders, the clinical record and the people directing the billing. We stay beside you throughout the case and bring in laboratory fraud whistleblower lawyers who know toxicology billing.